News2018-11-08T10:13:58+00:00

News

17March 2019

Deep Dive: Afatinib+Cetuximab for T790M Neg Patients With Acquired Resistance

Research, Treatments|

*March 2019*  This is an overview (written by Donald Ox) of the current EGFR TKIs and acquired resistance leading to the effectiveness of the afatinib + cetuximab combo treatment especially useful for T790M negative patients who developed acquired resistance to

14March 2019

Novel and Innovative Approach to Monitoring Disease Progression in Cancer on Horizon  

Research, Treatments|

*March 2019* Currently available for research purposes only, the Signatera (RUO) is the first ctDNA (circulating tumor DNA) assay custom-built for treatment monitoring and minimal residual disease (MRD) assessment. The test is being developed by Natera and is not yet

3February 2019

A cancer researcher reflects on the evolution of lung cancer therapies

Research, Treatments|

*January 2019* Harvard Health Publishing, Harvard Medical School, by Stephen Lyons.   When Dr. Lecia Sequist was undergoing her training to become a medical oncologist at Massachusetts General Hospital (MGH) in the early 2000s, the treatments available for lung cancer

3February 2019

Continuing Osimertinib Treatment After Progression Prolongs Survival Benefit in NSCLC

Research, Treatments|

*January 25, 2019* Targeted Oncology, Tony Berberabe. Patients who continued receiving osimertinib (Tagrisso) after their non–small cell lung cancer (NSCLC) had progressed demonstrated a prolonged benefit beyond the initial progression event, according to a retrospective analysis of 118 patients from

5January 2019

OncTalk 2018 – Local Therapies for Metastatic Lung Cancer – Who, What, Why, When and How?

Research, Treatments|

*November 10, 2018* GRACE partnered with Swedish Cancer Institute to present a discussion on Local Therapies for Metastatic Lung Cancer. Videos from the live webcast: Newer Technologies in Radiation; Novel Indications for Local Therapy in Advanced NSCLC; Systemic Therapies

22November 2018

PATIENTS LAUNCH NEW STUDY TO SHED LIGHT ON EGFR-POSITIVE LUNG CANCERS

Research, Treatments|

Scientists, physicians and patients collaborate to improve treatment for rare cancer SAN CARLOS, CA (November 14, 2018) — The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology and EGFR Resisters today announced the launch of a new study to create a novel bank of patient derived

22November 2018

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Research, Treatments|

*NATURE COMMUNICATIONS | (2018) 9:4655 | DOI: 10.1038/s41467-018-07078-0 | www.nature.com/naturecommunications * The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. In a subgroup of these patients we identified an association between

Living with EGFR

Supporting Research

Finding Hope

Join Us.

Welcome to the data gathering entry point for the EGFR Resisters Group! Please make sure only one survey is completed for each patient; caregivers can complete the survey if the patient/loved one has not already done so.